2023
DOI: 10.3390/jcm12165252
|View full text |Cite
|
Sign up to set email alerts
|

Dinutuximab Beta Maintenance Therapy in Patients with High-Risk Neuroblastoma in First-Line and Refractory/Relapsed Settings—Real-World Data

Aleksandra Wieczorek,
Urszula Żebrowska,
Marek Ussowicz
et al.

Abstract: Dinutuximab beta is approved for the maintenance treatment of patients with high-risk neuroblastoma (HR-NB), including patients with relapsed/refractory (R/R) disease. However, the data on its use in real-world clinical practice is limited. We retrospectively reviewed the clinical records of 54 patients with HR-NB who received maintenance therapy with dinutuximab beta in first-line (37 patients) or R/R settings (17 patients) at three centers in Poland. Of the 37 patients who received first-line treatment, twen… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(3 citation statements)
references
References 31 publications
(73 reference statements)
0
3
0
Order By: Relevance
“…Limitations of our study include the small number of patients involved and the retrospective nature of the analysis, which is due to the rarity of the disease as well as the experimental nature of this treatment approach. The effectiveness and safety of dinutuximab beta have recently been demonstrated in a much larger cohort of patients with frontline or relapsed/refractory HRNB in real-world clinical practice [13]. Additionally, our cohort includes patients with relapsed HRNB who did not progress rapidly while receiving individual relapse treatment, and the side effects of relapse treatment prior haplo-SCT were not systematically assessed.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Limitations of our study include the small number of patients involved and the retrospective nature of the analysis, which is due to the rarity of the disease as well as the experimental nature of this treatment approach. The effectiveness and safety of dinutuximab beta have recently been demonstrated in a much larger cohort of patients with frontline or relapsed/refractory HRNB in real-world clinical practice [13]. Additionally, our cohort includes patients with relapsed HRNB who did not progress rapidly while receiving individual relapse treatment, and the side effects of relapse treatment prior haplo-SCT were not systematically assessed.…”
Section: Discussionmentioning
confidence: 99%
“…Local therapy alone-such as surgery, radiation, or local radioimmunotherapy-is unlikely to be sufficient and will need to be followed by systemic therapy. Immunotherapeutic approaches have been implemented in the frontline and relapsed settings to improve outcomes in patients with HRNB [13], with monoclonal antibody therapy directed against the disialoganglioside GD2 being the most established option. The human-mouse-chimeric monoclonal anti-GD2 antibody dinutuximab beta is approved in Europe as post-consolidation therapy for patients with HRNB [14].…”
Section: Introductionmentioning
confidence: 99%
“…Despite the success that chemotherapy and immunotherapy have seen with regard to treating cancer, it is evident that a subset of individuals with a specific type of cancer may prove refractory to chemotherapy, radiation, and/or immunotherapy treatments. Even when a "new" treatment such as Dinutuximab is introduced, questions about how to use it most effectively may still arise, e.g., [168]. This leads to the obvious question of how to use all of the information available to maximize the probability of obtaining effective treatments from the growing list of predictive and prognostic factors.…”
Section: Discussionmentioning
confidence: 99%